Eli Lilly And Stock Current Valuation
| LLY Stock | EUR 767.80 21.70 2.91% |
Valuation analysis of Eli Lilly helps investors to measure Eli Lilly's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Eli Lilly's price fluctuation is very steady at this time. Calculation of the real value of Eli Lilly is based on 3 months time horizon. Increasing Eli Lilly's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Eli stock is determined by what a typical buyer is willing to pay for full or partial control of Eli Lilly and. Since Eli Lilly is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eli Stock. However, Eli Lilly's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 767.8 | Real 728.25 | Hype 767.8 |
The intrinsic value of Eli Lilly's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Eli Lilly's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Eli Lilly and helps investors to forecast how Eli stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eli Lilly more accurately as focusing exclusively on Eli Lilly's fundamentals will not take into account other important factors: Eli Lilly and Company Current Valuation Analysis
Eli Lilly's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eli Lilly Current Valuation | 337.36 B |
Most of Eli Lilly's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly and is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eli Lilly and has a Current Valuation of 337.36 B. This is much higher than that of the Other sector and significantly higher than that of the Other industry. The current valuation for all Germany stocks is notably lower than that of the firm.
Eli Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.Eli Lilly is currently under evaluation in current valuation category among its peers.
Eli Fundamentals
| Current Valuation | 337.36 B | |||
| Price To Book | 35.04 X | |||
| Price To Sales | 11.53 X | |||
| Revenue | 28.54 B | |||
| EBITDA | 8.28 B | |||
| Net Income | 6.24 B | |||
| Total Debt | 15.35 B | |||
| Cash Flow From Operations | 7.26 B | |||
| Price To Earnings To Growth | 2.24 X | |||
| Total Asset | 48.81 B | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 48.81 B | |||
| Last Dividend Paid | 0.56 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Eli Stock
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.